Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib versus docetaxel in previously treated HER2 exon 20-mutated advanced non-squamous NSCLC
2020-000951-11Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pyrotinib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Aug 2020; status: completed.
02
Drugs
pyrotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000951-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000951-11.